The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases · 2026
Restoring well-being: quality of life improvements following dolutegravir-based therapy after antiretroviral failure.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lins-Kusterer Liliane, Brites Carlos, de Lacerda Marcus Vinícius Guimarães, Page Kimberly, Bahia Fabianna, Luz Estela, Ramalho Aline, Wagner Sandra, Arriaga Maria Belen, CODE research group collaborators
Аннотация
BACKGROUND: Dolutegravir-based antiretroviral therapy has improved virologic outcomes in people living with HIV; however, its effects on Health-Related Quality of Life (HRQoL), particularly among individuals with prior antiretroviral failure, remain insufficiently characterized. We aimed to compare HRQoL in people living with HIV initiating dolutegravir-based regimens, with or without previous antiretroviral failure.
METHODS: This multicenter study was conducted across 15 Brazilian HIV centers. Participants completed the RAND-36 questionnaire at baseline and after 12-months of dolutegravir-based therapy. HRQoL changes were assessed within groups and compared between groups using change scores over time.
RESULTS: A total of 439 participants were included in the longitudinal analysis, of whom 373 had no prior therapeutic failure and 66 had previous antiretroviral failure. Among participants with prior failure, significant improvements were observed in role-emotional functioning (Δ = 17.17; p = 0.010), social functioning (Δ = 10.79; p = 0.008), and pain (Δ = 10.66; p = 0.024), whereas HRQoL remained stable among individuals switching therapy without prior failure. Between-group comparisons demonstrated significantly greater improvements in role-emotional functioning, social functioning, pain, and general health among individuals with prior therapeutic failure.
CONCLUSIONS: Switching to dolutegravir-based therapy was associated with stable HRQoL among individuals on suppressive regimens and with significant improvements among those with prior antiretroviral failure. These findings support the relevance of psychosocial and patient-reported outcomes in the evaluation of treatment response in people living with HIV.
METHODS: This multicenter study was conducted across 15 Brazilian HIV centers. Participants completed the RAND-36 questionnaire at baseline and after 12-months of dolutegravir-based therapy. HRQoL changes were assessed within groups and compared between groups using change scores over time.
RESULTS: A total of 439 participants were included in the longitudinal analysis, of whom 373 had no prior therapeutic failure and 66 had previous antiretroviral failure. Among participants with prior failure, significant improvements were observed in role-emotional functioning (Δ = 17.17; p = 0.010), social functioning (Δ = 10.79; p = 0.008), and pain (Δ = 10.66; p = 0.024), whereas HRQoL remained stable among individuals switching therapy without prior failure. Between-group comparisons demonstrated significantly greater improvements in role-emotional functioning, social functioning, pain, and general health among individuals with prior therapeutic failure.
CONCLUSIONS: Switching to dolutegravir-based therapy was associated with stable HRQoL among individuals on suppressive regimens and with significant improvements among those with prior antiretroviral failure. These findings support the relevance of psychosocial and patient-reported outcomes in the evaluation of treatment response in people living with HIV.